Nivolumab extends survival in advanced melanoma

An immunomodulator that targets the PD-1 pathway effected sustained remission in 31% of patients who took it for advanced melanoma. Remission lasted a median of 2 years, with 1- and 2-year overall...

Field of Interest: Oncology
Type: News Item

Team planning cuts pancreatectomy readmissions

MIAMI BEACH – A combination of teamwork and leadership led to a 50% reduction in readmission after pancreatectomy in a large academic facility. The readmission rate at Indiana University Hospital...

Field of Interest: Gastroentero...
Type: News Item

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness